Association between thrombocytopenia and development of acute respiratory distress syndrome.
Pubmed ID: 41526940
Pubmed Central ID: PMC12888621
Journal: Respiratory research
Publication Date: Jan. 13, 2026
Grants: 2023
Authors: Siempos II, Price DR, Kotanidou A, Papoutsi E, Charalampaki E, Gkirgkiris K, Minatsi GM, Dimopoulou G, Orfanos SE, Dimopoulou I
Cite As: Charalampaki E, Gkirgkiris K, Price DR, Papoutsi E, Minatsi GM, Dimopoulou G, Orfanos SE, Dimopoulou I, Kotanidou A, Siempos II. Association between thrombocytopenia and development of acute respiratory distress syndrome. Respir Res 2026 Jan 13;27(1):46.
Studies:
- Prevention and Early Treatment of Acute Lung Injury (PETAL) Acetaminophen in Sepsis: Targeted Therapy to Enhance Recovery (ASTER)
- Prevention and Early Treatment of Acute Lung Injury (PETAL) Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS)
- Prevention and Early Treatment of Acute Lung Injury (PETAL) Network - Low Tidal Volume Universal Support Feasibility of Recruitment for Interventional Trial (LOTUS FRUIT)
- Prevention and Early Treatment of Acute Lung Injury (PETAL) Network – Vitamin D to Improve Outcomes by Leveraging Early Treatment (VIOLET)
Abstract
BACKGROUND: Given that platelets support the integrity of the alveolar-capillary membrane, it is conceivable that thrombocytopenia may be associated with development of acute respiratory distress syndrome (ARDS). Yet, clinical studies confirming such an association are limited. We endeavoured to examine whether thrombocytopenia is independently associated with development of ARDS in critically ill patients. METHODS: First, we performed a systematic review and meta-analysis of observational studies reporting the number of patients at risk for ARDS with versus without thrombocytopenia who eventually developed ARDS. Next, we performed a secondary analysis using individual patient-level data from three large randomized controlled trials to estimate whether thrombocytopenia (defined as < 100,000 platelets/µL) was independently associated with development of ARDS. RESULTS: In the meta-analysis, four observational studies (five cohorts) involving 3666 critically ill patients were included. Patients with versus without thrombocytopenia were more likely to develop ARDS [46.3% versus 33.2%; relative risk 1.41, 95% confidence intervals (CI) 1.23–1.63; <i>p</i> < 0.001]. In the secondary analysis, data from 2927 critically ill patients were analyzed. After adjustment for confounders, including severity of illness, thrombocytopenia was not independently associated with development of ARDS (odds ratio 1.57, 95% CI 0.95–2.60; <i>p</i> = 0.080). The association between platelet count (as a continuous variable) and development of ARDS was non-linear and appeared U-shaped. CONCLUSIONS: Thrombocytopenia may not be independently associated with development of ARDS after adjustment for important confounders, such as severity of illness. Thrombocytopenia may serve as a marker of severe illness and its association with ARDS may not represent a mechanistic relationship. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-025-03444-x.